scholarly journals Real-time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology

Author(s):  
Rachel E. Reingold ◽  
Jilliana Monnier ◽  
Marco Ardigò ◽  
Joseph R. Stoll ◽  
Maria C. Pena ◽  
...  
2021 ◽  
Vol 27 (3) ◽  
pp. S294-S295
Author(s):  
Rachel Reingold ◽  
Joseph R. Stoll ◽  
Jilliana Monnier ◽  
Camila Pena ◽  
Japbani Nanda ◽  
...  

2019 ◽  
Vol 181 (4) ◽  
pp. 829-831 ◽  
Author(s):  
I. Saknite ◽  
M. Gill ◽  
C. Alessi‐Fox ◽  
M. Byrne ◽  
M. Jagasia ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3278-3278
Author(s):  
Inga Saknite ◽  
Melissa Gill ◽  
Alessi-Fox Christi ◽  
Jeffrey P Zwerner ◽  
Julia S Lehman ◽  
...  

BACKGROUND. Cutaneous erythema and histopathology features in patients post allogeneic hematopoietic cell transplantation (HCT) are nonspecific, making it difficult to distinguish acute graft-versus-host disease (aGVHD) from engraftment syndrome, drug reactions, viral infections, and other etiologies. Biopsies from different locations on the same patient frequently differ in aGVHD grade, and serial biopsies of a single lesion are not possible. Proper biopsy site selection, timing, and serial noninvasive microscopic monitoring may improve our understanding and management of aGVHD. In this study, we tested the feasibility of noninvasive reflectance confocal microscopy (RCM) to detect key histopathology features of cutaneous aGVHD. STUDY POPULATION. We enrolled 11 patients with high clinical suspicion of cutaneous aGVHD, as determined by a transplant physician. In total, 16 lesions of cutaneous aGVHD-affected site were imaged by RCM (6x6 mm2en face images at four different depths) and subsequently biopsied (4x4 mm punch biopsy). 9 out of 11 patients had only skin involvement, and 2 patients had skin and gut aGVHD. 5 patients had >50% body surface area (BSA) affected, 1 had 18-50% BSA, and 5 had <18% BSA. 8 out of 11 patients required systemic corticosteroids and 3 patients received topical corticosteroids. All patients were imaged before starting treatment. METHODS. We used a clinical confocal microscope (Vivascope 1500, Caliber I.D.), which enables real-time evaluation of epidermal and superficial dermal tissue at sub-cellular resolution. Four reflectance confocal microscopists blinded to histopathology independently evaluated the presence or absence of 18 RCM features1. Concurrently, four dermatopathologists blinded to clinical and confocal information determined the presence or absence of 19 histopathology features, as well as the Lerner aGVHD grade. A histologic feature was determined as "present" in a lesion when marked by most experts (expert vote) or resolved by a fifth expert in case of a disagreement among four experts. The reflectance confocal microscopist vote was then correlated to the dermatopathologist expert vote for 17 overlapping features. We also evaluated the interrater variability among microscopists and among dermatopathologists. RESULTS. The main aGVHD features by Lerner grade had > 88% correlation between RCM and histopathology: (1) basal vacuolar change, (2) presence of dyskeratotic keratinocytes, and (3) dermal inflammation. By contrast, dyskeratotic cells and inflammation at the adnexal structures had <50% correlation. This may be attributed to the fact that more adnexal structures are typically visible in the 6x6 mm2 RCM horizontal tissue view compared to vertical section histopathology. We found a similar interrater variability among RCM experts (70%) and dermatopathologists (68%). CONCLUSIONS. In this pilot study, we show that noninvasive label-free RCM of skin enables detection of the main Lerner grade features of cutaneous aGVHD. We found a similar interrater variability among reflectance confocal microscopists and among dermatopathologists who each independently evaluated the presence or absence of a list of aGVHD features. Future studies can build on this work to evaluate the feasibility of RCM to determine cutaneous aGVHD grade, as well as distinguish between rash due to aGVHD and drug reactions. ACKNOWLEDGEMENT. This work was supported in part by Career Development Award Number IK2 CX001785 from the United Sates Department of Veterans Affairs Clinical Science R&D (CSRD) Service. Saknite I, Gill M, Alessi-Fox C, Byrne M, Jagasia M, Gonzalez S, Ardigo M, Tkaczyk ER. Features of cutaneous acute graft-versus-host disease by reflectance confocal microscopy. Br J Dermatol (2019). Disclosures Christi: Caliber I.D.: Employment, Equity Ownership. Byrne:Karyopharm: Research Funding. Jagasia:Kadmon: Consultancy; Incyte: Consultancy; Janssen: Research Funding. Tkaczyk:Incyte: Consultancy.


2012 ◽  
Vol 144 (1-2) ◽  
pp. 33-40 ◽  
Author(s):  
Takahiro Yamazaki ◽  
Kazunori Aoki ◽  
Yuji Heike ◽  
Sung-Won Kim ◽  
Takahiro Ochiya ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4592-4592
Author(s):  
Alejandro Contento-Gonzalo ◽  
Antonio JiménezVelasco ◽  
Manuel Barrios ◽  
José Román-Gómez ◽  
Antonio P. Torres Gomez ◽  
...  

Abstract Background and objetives: Acute graft versus host disease (aGVHD) represents one of the main causes of death in patients who receive allogeneic stem cells transplantation (SCT). Quantification of hematopoietic chimerism by real-time PCR allows the detection of residual receptor cells with a high sensitivity (0.01%). Since aGVHD is supposed to be produced by reactivity of donor cells against host cells, this study was designed to relate the appearance of aGVHD with the amount of receptor cells remaining early after SCT. Patients and methods: Since January 2003, twenty seven patients who underwent myeloablative allogeneic SCT for acute leukemia (48% myeloid) could be included in the study (a minimum of 100 days follow-up was required). A sibling donor was used in 18 cases (67%) and bone marrow was the source of stem cells in 15 transplants (only in 2 cases the source was umbilical cord blood whereas the remaining were collected from peripheral blood). Conditioning with total body irradiation (TBI) was performed in 9 cases (33%). All the patients received the same GVHD prophylaxis with cyclosporine and methotrexate. Chimerism was determined by quantitative real-time PCR amplification of null alleles or insertion/deletion polymorphisms as previously described (Leukemia2005; 19: 336–43). Granulocytic engraftment, defined by the presence of more than 0.5 ×10e9/L granulocytes in two consecutive determinations, appeared at a median of 14 days (11–27) in our series. At least one chimerism sample had to be collected in the next week after granulocytic engraftment. Risk factors related to aGVHD were recorded and analyzed using Chi square for qualitative variables and non parametric tests for quantitative variables. Multivariate analysis was performed using Cox regression. Results: Eleven patients (40%) presented aGVHD (grade II–IV) in our series. Median receptor chimerism at the time of engraftment was 0.27% (0.01–7), showing significantly lower levels in patients who developed aGVHD (0.10 vs 0.57%, p=0.001 Mann-Whitney test). A chimerism value of 0.1% at the time of granulocytic engraftment was used to classify patients. COR curves were plotted previously for a better selection of the cut-off point. At 0.1% or lower, 8 of 9 patients (89%) developed aGVHD, whereas only 3 of 18 patients above this value presented aGVHD signs (p&lt;0.001, Chi-square test). In those patients who implanted before aGVHD onset (7 of 11, 64%), median time between chimerism determination and clinical appearance of aGVHD was 8 days (1–31). Univariant analysis showed only 3 significant variables in relation to the development of aGVHD: TBI conditioning (p=0.029, log rank test), unrelated donor (p=0.013) and low level of receptor chimerism (p=0.0002). In the multivariate study, only chimerism remained as a significant variable (p&lt;0.001, Cox regression). Interpretation and conclusions: Our data show that early monitoring of chimerism may be useful for identification of patients at risk of developing aGVHD after SCT. With the quantitative method used, a low chimerism receptor level at the time of engraftment (0.1% or lower) predicts the onset of aGVHD and can anticipate it in more than one week. This could allow the use of measures destined to reduce aGVHD in higher risk patients.


2017 ◽  
Vol 255 (12) ◽  
pp. 2389-2397 ◽  
Author(s):  
Tudor C. Tepelus ◽  
Gloria B. Chiu ◽  
Jyotsna Maram ◽  
Jianyan Huang ◽  
Vikas Chopra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document